title: [Curative resection for bulky rectal gastrointestinal stromal tumor after neoadjuvant imatinib mesylate].
abstract: Gastrointestinal stromal tumor is the most common mesenchymal tumor of the gastrointestinal tract. However, the frequency of rectal gastrointestinal stromal tumor is relatively low. We described the case of a 54-year-old man with bulky rectal gastrointestinal stromal tumor of which a diameter was 10 cm. After eight-week neoadjuvant imatinib mesylate, the diameter of tumor was reduced to 6 cm. The patient did not have any distant metastases on preoperative computed tomography and magnetic resonance imaging. He underwent abdominoperineal resection. The radial margin was negative. Immunohistochemical staining showed that KIT and CD34 were positive. The number of mitosis was 13 per 50 high-power fields. Adjuvant imatinib mesylate was administered for one year. No recurrence was found for 43 months after a curative resection. Curative resection is the most promising treatment for gastrointestinal stromal tumor. However, neoadjuvant imatinib mesylate followed by surgical procedure seems to be one of the treatment options for locally advanced gastrointestinal stromal tumor.
authors.affiliation: Dept. of Surgical Oncology, Graduate School, Tokyo Medical and Dental University.
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Kobayashi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Uetake
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Higuchi
authors.forename: Masayuki
authors.initials: M
authors.lastname: Enomoto
authors.forename: Masamichi
authors.initials: M
authors.lastname: Yasuno
authors.forename: Satoru
authors.initials: S
authors.lastname: Iida
authors.forename: Tetsunori
authors.initials: T
authors.lastname: Yoshimura
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Ishikawa
authors.forename: Megumi
authors.initials: M
authors.lastname: Ishiguro
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Kato
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ono
authors.forename: Akifumi
authors.initials: A
authors.lastname: Kikuchi
authors.forename: Shinichi
authors.initials: S
authors.lastname: Yamauchi
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sugihara
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D003131:Combined Modality Therapy; D046152:Gastrointestinal Stromal Tumors / Q000473:pathology / Q000628:therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D012004:Rectal Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate